Last updated: September 5, 2026
Betamethasone dipropionate and clotrimazole is a mature topical combination used for inflammatory fungal skin infections. The reference product, Lotrisone cream, combines the corticosteroid betamethasone dipropionate at 0.05% with the antifungal clotrimazole at 1%. U.S. commercial value is concentrated in low-cost generic creams, while the branded product has limited strategic importance. The market has minimal patent protection, low regulatory barriers for standard creams, and high substitution risk.
The product’s financial trajectory follows a classic off-patent pattern: high historical value during the branded period, rapid erosion after generic entry, and a later phase dominated by manufacturing efficiency, pharmacy contracting, private-label supply, and distribution scale. Public companies generally do not disclose revenue for this combination separately.
What is the betamethasone dipropionate and clotrimazole product?
The combination is a prescription topical cream for dermatophyte and yeast infections accompanied by inflammatory symptoms. Lotrisone contains:
| Attribute |
Product detail |
| Active ingredients |
Clotrimazole 1%; betamethasone dipropionate 0.05% |
| Dosage form |
Topical cream |
| Original brand |
Lotrisone |
| U.S. regulatory pathway |
New drug application, followed by abbreviated new drug applications for generics |
| Therapeutic category |
Topical antifungal plus topical corticosteroid |
| Main indications |
Tinea corporis, tinea cruris, and tinea pedis |
| U.S. prescription status |
Prescription product |
| Reference sponsor history |
Schering-Plough; later commercial ownership associated with Merck |
| Current market structure |
Multiple generic manufacturers and private-label suppliers |
The combination is intended for short-term use when fungal infection and inflammation coexist. The corticosteroid component creates clinical and labeling limitations. Topical corticosteroids can mask infection, worsen certain fungal infections, cause skin atrophy, and create systemic exposure when used over large areas or under occlusion. The FDA label limits duration and discourages use in children under 17 years of age for the combination product.[1]
What is the FDA regulatory status of Lotrisone?
Lotrisone was approved in the United States under NDA 018937. The product was originally commercialized by Schering-Plough and later associated with Merck’s prescription dermatology portfolio. FDA labeling identifies the active ingredients as clotrimazole and betamethasone dipropionate in a cream formulation.[1]
The reference product is now commercially less important than generic equivalents. FDA regulatory activity is concentrated in ANDA products rather than new clinical development. Generic applicants generally rely on the reference product’s established safety and efficacy findings and must demonstrate pharmaceutical equivalence and bioequivalence or comparable product performance under the applicable topical-product requirements.
What strengths and formulations are marketed?
The principal U.S. formulation is a cream containing:
- Clotrimazole 1%
- Betamethasone dipropionate 0.05%
The product is applied topically to affected skin. Cream is the commercially established dosage form. Ointment, lotion, spray, and combination products with different corticosteroids may compete clinically, but they are not automatically substitutable for the clotrimazole-betamethasone cream.
Formulation competition is primarily commercial rather than patent-driven. Suppliers compete on:
- Tube size
- Cream texture and spreadability
- Packaging
- Preservative system
- Manufacturing cost
- Wholesaler and pharmacy contracts
- Authorized-generic or private-label supply
What patents protect betamethasone dipropionate and clotrimazole?
No material U.S. composition-of-matter patent protection remains for the active ingredients or the established combination. Both clotrimazole and betamethasone dipropionate are long-established small-molecule ingredients with expired underlying patent rights.
The commercial patent position is therefore weak for the conventional cream. The relevant protection historically would have involved:
| Patent category |
Current commercial relevance |
| Active-ingredient patents |
Expired |
| Original combination patents |
Expired or no longer commercially blocking |
| Conventional cream formulation patents |
No material blocking estate identified for the standard product |
| Method-of-use patents |
Limited practical value for the established indications |
| Manufacturing patents |
Potentially relevant to individual suppliers but not a broad market barrier |
| Device or delivery patents |
Not material for the standard tube-based cream |
The absence of meaningful patent protection does not eliminate regulatory or manufacturing barriers. A generic applicant still must meet FDA requirements for identity, strength, quality, purity, stability, labeling, and product performance. Those barriers are manageable and have not prevented broad generic availability.
What is the Orange Book status of Lotrisone?
The Orange Book is the principal U.S. source for approved drug products, therapeutic equivalence evaluations, and listed patent or exclusivity information.[2] For a mature topical combination such as Lotrisone, the important commercial conclusion is that the product does not have an active patent or exclusivity position capable of preventing generic competition.
The reference NDA is relevant as the regulatory benchmark, but generic manufacturers are the principal market participants. Orange Book status should be reviewed at the current product and NDA level because FDA listings can change as sponsors update marketing status, withdraw products, or transfer applications.
How many patents cover the product?
The number of commercially relevant blocking patents is effectively zero for the standard U.S. cream formulation. Historical patents may appear in older patent records, but expired rights do not constrain current entry.
The more relevant question is whether a supplier has a live patent covering a differentiated formulation, manufacturing process, or delivery system. Such a patent would need to provide commercially meaningful claim scope and withstand validity and infringement challenges. No broad, market-defining patent estate is associated with the conventional clotrimazole 1% and betamethasone dipropionate 0.05% cream.
When does betamethasone dipropionate and clotrimazole lose exclusivity?
The product lost practical exclusivity years ago. Lotrisone’s current market is post-exclusivity and genericized.
| Lifecycle event |
Commercial implication |
| Original approval in the 1980s |
Established the reference product and clinical market |
| Expiration of historical patent rights |
Removed the principal legal barrier to generic development |
| Generic approvals |
Shifted volume from the brand to low-cost equivalents |
| Mature generic competition |
Reduced prices and compressed supplier margins |
| Current period |
Demand is driven by prescribing, payer coverage, availability, and contract pricing |
No meaningful period of remaining U.S. regulatory exclusivity is expected to protect the mature product. New exclusivity would require a qualifying new formulation, indication, or other statutory basis, not merely continued sale of the established cream.
Which companies compete in the market?
The market includes the reference-product sponsor, generic prescription manufacturers, contract manufacturers, and distributors. The precise manufacturer mix varies by pharmacy, wholesaler, national drug code, and time period.
Competition generally comes from:
- Manufacturers with approved ANDAs for clotrimazole and betamethasone dipropionate cream
- Authorized-generic suppliers
- Contract manufacturers serving dermatology marketers
- Retail pharmacy and wholesaler private-label programs
- Alternative topical antifungal and corticosteroid products
The competitive landscape is fragmented at the supplier level but concentrated at the distribution level. Large wholesalers and pharmacy chains can influence net pricing because the product is clinically familiar, inexpensive to manufacture, and readily substituted.
Which companies are challenging Lotrisone, and are there Paragraph IV risks?
Generic companies have challenged the product commercially through ANDA approvals and market entry rather than through a current high-profile Paragraph IV litigation campaign.
Paragraph IV certifications are most important when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. For a mature combination with no material blocking patent estate, Paragraph IV risk is low. The principal competitive risk is ordinary generic entry, not an active patent dispute.
A supplier seeking to commercialize a materially different formulation could face a different legal analysis. A new patent covering a formulation or delivery system could create Paragraph IV exposure if listed in the Orange Book and if the product fell within the patent claims. That scenario does not describe the standard cream market.
What patent litigation affects the product?
No major current U.S. patent litigation is associated with the standard clotrimazole-betamethasone cream in the public market profile of the product. The absence of litigation reflects the age of the product and the lack of a valuable, enforceable blocking patent position.
Potential disputes would more likely concern:
- ANDA product quality
- Trademark or trade-dress rights
- Contract manufacturing
- Supply agreements
- State substitution rules
- Product liability
- Labeling and promotional conduct
These issues can affect individual suppliers but are unlikely to restore branded exclusivity.
What is the generic launch outlook?
Generic launch risk is high because the market is already open and the product has limited differentiation. A new entrant would not need to overcome a substantial patent barrier, but it would face commercial pressure from incumbent suppliers.
Base-case launch scenario
The most likely launch model is a low-price prescription generic supplied through wholesalers and retail pharmacies. Success depends on:
- FDA approval and commercial readiness.
- Reliable API and tube supply.
- Wholesaler acceptance.
- Competitive acquisition cost.
- Pharmacy availability.
- Ability to maintain quality and avoid backorders.
Upside scenario
A supplier could achieve stronger economics through:
- A supply agreement with a large pharmacy chain
- Authorized-generic distribution
- A differentiated package size
- International registration
- A broader dermatology portfolio
- Reliable supply during competitor shortages
Downside scenario
Margins can deteriorate quickly if several suppliers compete for the same contracts. The product has limited brand loyalty and low switching costs. A manufacturing deviation, shortage, or regulatory warning can remove a supplier from preferred distribution channels.
What is the financial trajectory for the product?
The financial trajectory is mature and defensive rather than growth-oriented.
| Period |
Revenue pattern |
Margin profile |
Main value driver |
| Branded launch and early adoption |
Rising branded sales |
High branded margins |
Physician adoption and dermatology demand |
| Generic entry |
Rapid brand erosion |
Declining brand margins |
Remaining brand prescriptions and distribution |
| Mature generic phase |
Stable or declining nominal market value |
Low-to-moderate supplier margins |
Cost control and volume |
| Current market |
Low unit prices with recurring demand |
Contract-dependent |
Manufacturing efficiency and supply reliability |
Public financial reports do not typically isolate revenue for Lotrisone or for the active-ingredient combination. Merck reports at broader business-segment levels, and generic manufacturers generally disclose portfolio or segment revenue rather than sales for individual mature topical products.[3]
The product’s economic value is therefore better assessed through market structure than through disclosed brand revenue. Key metrics include:
- Annual prescription volume
- Average selling price per tube
- Number of approved suppliers
- Generic acquisition cost
- Reimbursement and payer coverage
- Wholesaler inventory
- Backorder frequency
- Supplier concentration
- International sales
- Cost of goods and tube-filling capacity
A mature product can remain commercially useful despite low per-unit pricing because manufacturing is relatively straightforward and clinical demand is recurring. Its value is strongest for a supplier that already has topical manufacturing, regulatory infrastructure, and pharmacy distribution.
How strong is the patent estate compared with competing topical drugs?
The patent estate is weaker than the estates for newer topical antifungals, corticosteroid formulations, and branded dermatology products with proprietary vehicles or delivery systems.
| Product type |
Patent strength |
Generic-entry risk |
Commercial profile |
| Clotrimazole-betamethasone conventional cream |
Low |
High |
Mature, price-sensitive |
| New topical antifungal formulation |
Moderate to high |
Lower during patent term |
Differentiated formulation value |
| Branded topical corticosteroid with proprietary vehicle |
Moderate to high |
Depends on listed patents |
Higher pricing potential |
| OTC clotrimazole monotherapy |
Low |
High |
Broad retail competition |
| Generic corticosteroid monotherapy |
Low |
High |
Large substitution market |
The combination benefits from a recognizable treatment concept but lacks durable exclusivity. Its clinical convenience may support prescribing, but the two active ingredients can often be prescribed separately or replaced with other topical regimens.
What are the main substitutes and competitive threats?
The largest competitive threat is not a patented replacement. It is therapeutic substitution.
Relevant alternatives include:
- Clotrimazole monotherapy
- Terbinafine topical products
- Ketoconazole topical products
- Miconazole topical products
- Nystatin for selected fungal infections
- A separate antifungal plus a separate topical corticosteroid
- Other corticosteroid-antifungal combinations
Clinical guidelines often favor use of an appropriate antifungal without a corticosteroid when inflammation does not justify combination therapy. This creates a long-term substitution risk for clotrimazole-betamethasone products.[4]
The combination can remain attractive where rapid reduction of itching and inflammation affects adherence, but prolonged or inappropriate corticosteroid use limits its position.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are operational rather than patent-based. A supplier must manage:
- Consistent micronization and dispersion of betamethasone dipropionate
- Uniform clotrimazole content
- Cream rheology and phase stability
- Microbial limits
- Tube-filling accuracy
- Container-closure compatibility
- Stability across the labeled shelf life
- Cleaning validation for potent corticosteroid residues
- Batch-to-batch content uniformity
Betamethasone dipropionate is used at a low concentration, which increases the importance of blend uniformity and analytical sensitivity. Although the product is not technically comparable to a complex biologic, topical semisolid manufacturing can create quality problems if process controls are weak.
The API supply chain is globally available. The principal risks are supplier qualification, geopolitical disruption, regulatory inspection findings, and shortages of packaging or filling capacity.
What licensing deals affect the product?
No major recent licensing transaction is required to explain the current market. The original commercial rights were associated with Schering-Plough and later Merck. The post-exclusivity market depends more on ANDA ownership, contract manufacturing, and distribution agreements than on traditional branded licensing.
Potential transaction value is limited unless a deal includes:
- A broad dermatology product portfolio
- Existing pharmacy contracts
- International rights
- Manufacturing capacity
- An authorized-generic arrangement
- A differentiated formulation with regulatory or patent protection
A standalone acquisition of rights to the conventional cream would likely have limited strategic value because multiple generic alternatives exist.
What is the geographic market outlook?
The combination is sold or has been sold in multiple countries, but regulatory status and brand names vary. Outside the United States, market dynamics depend on:
- National prescription rules
- Generic substitution policy
- Local registration
- Government price controls
- Pharmacy purchasing structure
- Dermatology prescribing patterns
- Availability of clotrimazole and corticosteroid monotherapies
The United States is a highly genericized market. In emerging markets, branded-generics can retain more pricing power, but local competition and regulatory fragmentation reduce the value of a single global patent strategy.
Key Takeaways
- Betamethasone dipropionate and clotrimazole is a mature topical combination marketed historically as Lotrisone.
- The standard U.S. cream contains clotrimazole 1% and betamethasone dipropionate 0.05%.
- Practical exclusivity has expired, and generic competition is well established.
- No material blocking patent estate protects the conventional cream.
- Paragraph IV and patent-litigation risk are low compared with the risk of ordinary generic price competition.
- The market is driven by manufacturing cost, wholesaler access, pharmacy contracts, and supply reliability.
- Public companies do not generally disclose product-level revenue for this combination.
- Long-term substitution by antifungal monotherapy and other topical regimens limits growth.
- Commercial value remains for efficient manufacturers with topical capacity and distribution scale.
- A differentiated formulation or delivery system would have greater strategic value than the established cream.
FAQs
Is Lotrisone still under patent protection?
No material patent protection remains for the conventional clotrimazole 1% and betamethasone dipropionate 0.05% cream.
Is clotrimazole-betamethasone available over the counter?
In the United States, the combination is prescription-only. Clotrimazole monotherapy is available over the counter in several markets, including the United States.
Does the product have biosimilar competition?
No. Biosimilars apply to biologic products. Clotrimazole and betamethasone dipropionate are small-molecule drugs, so competition occurs through generic-drug pathways.
Can a new formulation obtain patents?
Yes. A genuinely novel vehicle, delivery system, formulation, or manufacturing process could receive patent protection if it satisfies patentability requirements. The patent would protect the new technology, not automatically the established cream.
Is the combination commercially stronger than clotrimazole alone?
It can command clinical use where inflammation and fungal infection coexist, but clotrimazole alone has broader retail availability and lower regulatory complexity. The combination faces greater safety and labeling constraints because of the corticosteroid component.
References
-
U.S. Food and Drug Administration. (n.d.). Lotrisone (clotrimazole and betamethasone dipropionate) cream prescribing information. FDA Drugs@FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
-
Merck & Co., Inc. (2023). Annual report 2023. Merck & Co., Inc.
-
American Academy of Family Physicians. (2014). Diagnosis and management of tinea infections. American Family Physician, 90(10), 702-710.
